Autologous stem-cell transplantation as first-line therapy in peripheral t-cell lymphomas: Results of a prospective multicenter study

Journal of Clinical Oncology

Volumn 27, Issue 1, 2009, Pages 106-113

  Reimer, Peter ^a   Rüdiger, Thomas ^a   Geissinger, Eva ^a   Weissinger, Florian ^a   Nerl, Christoph ^a   Schmitz, Norbert ^a   Engert, Andreas ^a   Einsele, Hermann ^a   Muller Hermelink, Hans Konrad ^a   Wilhelm, Martin ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, NEOPLASM; FEMALE; GLYCOPROTEINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 58149347800     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.4870     Document Type: Article

References (58)

1. Ascani S, Zinzani P L, Gherlinzoni F, et al: Peripheral T-cell lymphomas: Clinico-pathologic study of 168 cases diagnosed according to the REAL classification. Ann Oncol 8: 583-592, 1997
2. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89: 3909-3918, 1997
3. Rüdiger T, Weisenburger D D, Anderson J R, et al: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 13: 140-149, 2002
4. Swerdlow S H, Habeshaw J A, Rohatiner A Z, et al: Caribbean T-cell lymphoma/leukemia. Cancer 54: 687-696, 1984
5. Nakamura S, Suchi T, Koshikawa T, et al: Clinicopathologic study of 212 cases of peripheral T-cell lymphoma among the Japanese. Cancer 72: 1762-1772, 1993
6. Montalbán C, Obeso G, Gallego A, et al: Peripheral T-cell lymphoma: A clinicopathological study of 41 cases and evaluation of the prognostic significance of the updated Kiel classification. Histopathology 22: 303-310, 1993
7. Lee S S, Cho K J, Kim C W, et al: Clinicopathological analysis of 501 non-Hodgkin's lymphomas in Korea according to the revised European-American classification of lymphoid neoplasms. Histopathology 35: 345-354, 1999
8. Armitage J O, Vose J M, Linder J, et al: Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol 7: 1783-1790, 1989
9. Gisselbrecht C, Gaulard P, Lepage E, et al: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas: Groupe d'Etudes des Lymphomes de I'Adulte (GELA). Blood 92: 76-82, 1998
10. Melnyk A, Rodriguez A, Pugh W C, et al: Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89: 4514-4520, 1997
11. Coiffier B, Brousse N, Peuchmaur M, et al: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen-The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1: 45-50, 1990
12. Lippman S M, Miller T P, Spier C M, et al: The prognostic significance of the immunotype in diffuse large-cell lymphoma: A comparative study of the T-cell and B-cell phenotype. Blood 72: 436-441, 1988
13. Ansell S M, Habermann T M, Kurtin P J, et al: Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 15: 2296-2301, 1997
14. Zaja F, Russo D, Silvestri F, et al: Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: Clinical characteristics and outcome. Haematologica 82: 171-177, 1997
15. Sonnen R, Schmidt W P, Müller-Hermelink H K, et al: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 129: 366-372, 2005
16. Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspecified (PTCL-U):Aa new prognostic model from a retrospective multicentric clinical study. Blood 103: 2474-2479, 2004
17. Gascoyne R D, Aoun P, Wu D, et al: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93: 3913-3921, 1999
18. Falini B, Pileri S, Zinzani P L, et al: ALK + lymphoma: Clinico-pathological findings and outcome. Blood 93: 2697-2706, 1999
19. Armitage J O, Greer J P, Levine A M, et al: Peripheral T-cell lymphoma. Cancer 63: 158-163, 1989
20. López-Guillermo A, Cid J, Salar A, et al: Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification. Ann Oncol 9: 849-855, 1998
21. Savage K J, Chhanabhai M, Gascoyne R D, et al: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15: 1467-1475, 2004
22. Vose J M: International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood 106:239a, 2005 (suppl; abstr 811)
23. Vose J M, Peterson C, Bierman P J, et al: Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood 76: 424-431, 1990
24. Fanin R, Ruiz de Elvira M C, Sperotto A, et al: Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: Analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 23: 437-442, 1999
25. Haider K, Zamkoff K, Gentile T C: High dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) in peripheral T-cell lymphoma (PTCL): A single institution experience. Blood 94: 173a, 1999 (suppl; abstr 753)
26. Rodriguez J, Munsell M, Yazji S, et al: Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19: 3766-3770, 2001
27. Blystad A K, Enblad G, Kvaloy S, et al: High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27: 711-716, 2001
28. Song K W, Mollee P, Keating A, et al: Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: Variable outcome according to pathological subtype. Br J Haematol 120: 978-985, 2003
29. Rodriguez J, Caballero M D, Gutierrez A, et al: High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: The GEL-TAMO experience. Ann Oncol 14: 1768-1775, 2003
30. Jagasia M, Morgan D, Goodman S, et al: Histology impacts the outcome of peripheral T-cell lymphomas after high-dose chemotherapy and stem cell transplant. Leuk Lymphoma 45: 2261-2267, 2004
31. Jantunen E, Wiklund T, Juvonen E, et al: Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: A nationwide survey. Bone Marrow Transplant 33: 405-410, 2004
32. Schetelig J, Fetscher S, Reichle A, et al: Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88: 1272-1278, 2003
33. Kewalramani T, Zelenetz A D, Teruya-Feldstein J, et al: Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134: 202-207, 2006
34. Reimer P, Schertlin T, Rüdiger T, et al: My-eloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation (APBSCT) as first-line therapy in peripheral T cell lymphomas (PTCL): First results of a prospective multicenter study. Hematol J 5: 304-311, 2004
35. Cheson B D, Horning S J, Coiffier B, et al: Report of an international workshop to standardize criteria for non-Hodgkin's lymphomas. J Clin Oncol 17: 1244-1253, 1999
36. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-A Groupe d'Etude des Lymphomes de I'Adulte study. J Clin Oncol 18: 3025-3030, 2000
37. Gisselbrecht C, Lepage E, Molina T, et al: Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20: 2472-2479, 2002
38. Mounier N, Simon D, Haioun C, et al: Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 20: 1426-1427, 2002
39. Mounier N, Gisselbrecht C, Briére J, et al: All aggressive lymphoma subtypes do not share the same similar outcome after front-line autotransplantation: A matched-control analysis by the Group d'Etude des Lymphomes de I'Adulte (GELA). Ann Oncol 15: 1790-1797, 2004
40. Mounier N, Gisselbrecht C, Briére J, et al: Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotrans-plantation after complete remission: A cohort study by the Group d'Etude des Lymphomes de I'Adulte (GELA). J Clin Oncol 22: 2826-2834, 2004
41. Rodríguez J, Conde E, Gutiérrez A, et al: Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: The GELTAMO experience. Eur J Haematol 78: 290-296, 2007
42. Yamazaki T, Sawada U, Kura Y, et al: Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy: A single institution study. Acta Haematol 116: 90-95, 2006
43. Rodríguez J, Conde E, Gutiérrez A, et al: The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: The Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18: 652-657, 2007
44. Feyler S, Prince H M, Pearce R, et al: The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study. Bone Marrow Transplant 40: 443-450, 2007
45. Kyriakou C, Canals C, Goldstone A, et al: High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26: 218-224, 2008
46. Rodriguez J, Conde E, Gutiérrez A, et al: Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from the Gel-Tamo Study Group. Eur J Haematol 79: 32-38, 2007
47. Corradini P, Tarella C, Zallio F, et al: Long-term follow-up of patients with peripheral T-cell lympho-mas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20: 1533-1538, 2006
48. Mercadal S, Briones J, Xicoy B, et al: Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with in peripheral T-cell lymphoma. Ann Oncol 19: 958-963, 2008
49. D'Amore F, Relander T, Lauritzsen G, et al: Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL): A phase II study of the Nordic Lymphoma Group (NLG). Blood 108: 123a, 2006 (suppl; abstr 401)
50. Savage K J, Harris N L, Vose J M, et al: ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-cell Lymphoma Project. Blood 111: 5496-5504, 2008
51. Shipp MA, Mauch P M, Harris N L: Non-Hodgkin's lymphomas, in DeVita V T, Hellmann S, Rosenberg S A (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 1997, pp 2165-2175
52. Rodriguez J, Conde E, Gutiérrez A, et al: The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 92: 1067-1074, 2007
53. Enblad G, Hagberg H, Erlanson M, et al: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103: 2920-2924, 2004
54. Trumper L H, Hohloch K, Kloess M, et al: CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003-1) and toxicity of a phase II trial of the German High Grade Non-Hodgkin's Lymphoma Group (DSHNHL). J Clin Oncol 24: 431, 2006 (suppl; abstr 7538)
55. Weidmann E, Hess G, Krause S W, et al: A phase II immunochemotherapy study with alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Blood 108:769a, 2006 (suppl; abstr 2721)
56. Kim J G, Sohn S K, Chae Y S, et al: Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: A phase II study. Cancer Chemother Pharmacol 60: 129-134, 2007
57. Gallamini A, Zaya F, Patti C, et al: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110: 2316-2323, 2007
58. Corradini P, Dodero A, Zallio F, et al: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation for hematopoietic cells. J Clin Oncol 22: 2172-2176, 2004